Itovebi savings card: as little as $0 a fill with commercial insurance

How to pay the least

Ask for the cash price

Itovebi

We didn’t find one.

Ask your pharmacy for Itovebi’s cash price, and one or two other pharmacies too.
Itovebi’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Genentech Patient Foundation. Do not have insurance coverage for their Genentech medicine and their household makes less than $150,000 per year Or call (888) 941-3331.

See if you qualify

Compare every option

Brand nameItovebi

Authorized genericinavolisib

Regular genericinavolisib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Itovebi?

The original

–

Brand nameThe maker’s card

Genentech Oncology Co-pay Assistance Program

Savings card from Genentech

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a fill

The card takes up to $25,000 a year off your co-pay.

Or call 1-888-249-4918.

In the maker’s words

“With the Genentech Oncology Co-pay Program, eligible patients with commercial insurance may pay as little as $0 per fill of Itovebi.”

From the maker’s offer on itovebi.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Itovebi itself, from the same company, sold without the brand name, and usually for less. For now Itovebi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

HR+, HER2- breast cancer with a PIK3CA mutation

What the FDA label says

ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.

Source: the FDA label for Itovebi (Genentech, Inc.), April 21, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/itovebi/